Search company, investor...

Huixin Yigu

Founded Year

2021

Stage

Seed VC | Alive

About Huixin Yigu

Huixin Yigu is a biopharmaceutical enterprise focusing on the field of cell therapy for neurological diseases. It uses reprogramming technology and a non-integrated system to directly induce neural stem cells (iNSCs) from human peripheral blood mononuclear cells or fibroblasts. The company was founded in 2021 and is based in Beijing, China.

Headquarters Location

Room 101, Floor 2-12, No. 6, District 1, No. 8 Shengyuan Road, Life Science Park, Changping District

Beijing, Beijing,

China

Missing: Huixin Yigu's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Huixin Yigu's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Huixin Yigu Frequently Asked Questions (FAQ)

  • When was Huixin Yigu founded?

    Huixin Yigu was founded in 2021.

  • Where is Huixin Yigu's headquarters?

    Huixin Yigu's headquarters is located at Room 101, Floor 2-12, No. 6, District 1, No. 8, Beijing.

  • What is Huixin Yigu's latest funding round?

    Huixin Yigu's latest funding round is Seed VC.

  • Who are the investors of Huixin Yigu?

    Investors of Huixin Yigu include Green Pine Capital Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.